An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs MGL-3196 (Primary)
- Indications Hyperlipoproteinaemia type IIa; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Madrigal Pharmaceuticals
- 27 Sep 2017 Status changed from active, no longer recruiting to completed.
- 11 Aug 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Jul 2017 New trial record